Intra-arterial reteplase for the treatment of acute limb ischemia.
The removal of urokinase from the market has created a dilemma for interventionists and vascular surgeons treating patients with acute limb threatening ischemia due to arterial thrombosis or embolization. Reteplase is a newer, fibrin-specific thrombolytic agent with properties that make it an attractive alternative to urokinase. We report two cases of successful treatment of acute, limb threatening ischemia with intra-arterial Reteplase therapy.
Laird
J R
JR
Cardiovascular Research Foundation, 110 Irving Street N.W., Suite 4B-1, Washington, D.C. 20010, USA. jrl2@mhg.edu
Dangas
G
G
Jaff
M
M
Satler
L F
LF
Mehran
R
R
Leon
M B
MB
D000208:Acute Disease; D000368:Aged; D000792:Angiography; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D005528:Foot / Q000098:blood supply*; D006801:Humans; D007261:Infusions, Intra-Arterial; D007511:Ischemia / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage*; D015912:Thrombolytic Therapy / Q000379:methods; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; C087896:reteplase; D010959:Tissue Plasminogen Activator